Recently major efforts have been made to define the oligometastatic setting, but for head and neck cancer (HNC) limited data are available. We aimed to evaluate outcome of oligometastatic HNC treated with Stereotactic body radiotherapy (SBRT) as metastasis-directed therapy.
Materials and methods
We analyzed patients treated with SBRT on a maximum of five oligometastases from HNC, in up to two organs. Concomitant treatment was allowed. End points were toxicity, local control of treated metastases (LC), progression-free survival (PFS) and overall survival (OS).
48 consecutive patients and 71 lesions were treated. With a follow-up of 20.2 months, most common primary tumors were larynx (29.2%) and salivary glands (29.2%), while common site of metastases was lung (59.1%). Median dose was 48 Gy (21–75) in 3–8 fractions. Treatment was well tolerated, with two patients reporting mild pain and nausea. LC rates at 1 and 2 years were 83.1% and 70.2%. Previous local therapy (HR 4.97; p = 0.002), oligoprogression (HR 4.07; p = 0.031) and untreated metastases (HR 4.19; p = 0.027) were associated with worse LC. PFS at 1 and 2 years were 42.2% and 20.0%. Increasing age (HR 1.03; p = 0.010), non-adenoid cystic carcinoma (HR 2.57; p = 0.034) and non-lung metastases (HR 2.20; p = 0.025) were associated with worse PFS. One- and 2-years OS were 81.0% and 67.1%. Worse performance status (HR 2.91; p = 0.049), non-salivary primary (HR 19.9; p = 0.005), non-lung metastases (HR 2.96; p = 0.040) were correlated with inferior OS.
SBRT can be considered a safe metastasis-directed therapy in oligometastatic HNC.
Efficacy of the treatment seems to be higher when administered upfront in the management of metastatic disease; however, selection of patients need to be improved due to the relevant risk of appearance of new metastatic site after SBRT.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bates JE, De Leo AN, Morris CG, Amdur RJ, Dagan R (2019) Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: single-institution outcomes. Head Neck 41(7):2309–2314. https://doi.org/10.1002/hed.25695
Bonomo P, Greto D, Desideri I et al (2019) Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal? Oral Oncol 93:1–7. https://doi.org/10.1016/j.oraloncology.2019.04.006
Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (Lond, Engl) 394(10212):1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7
Corbin KS, Hellman S, Weichselbaum RR (2013) Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 31(11):1384–1390. https://doi.org/10.1200/JCO.2012.45.9651
de Bree R, Senft A, Coca-Pelaz A et al (2018) Detection of distant metastases in head and neck cancer: changing landscape. Adv Ther 35(2):161–172. https://doi.org/10.1007/s12325-018-0662-8
Dudek W, AlMoussa E, Schreiner W, Mantsopoulos K, Sirbu H (2020) Survival and prognostic analysis after pulmonary metastasectomy for head and neck cancer. Thorac Cardiovasc Surg. https://doi.org/10.1055/s-0040-1713112
Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V (2001) Incidence and sites of distant metastases from head and neck cancer. ORL 63(4):202–207. https://doi.org/10.1159/000055740
Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252
Florescu C, Thariat J (2014) Local ablative treatments of oligometastases from head and neck carcinomas. Crit Rev Oncol Hematol 91(1):47–63. https://doi.org/10.1016/j.critrevonc.2014.01.004
Franzese C, Zucali PA, Di Brina L et al (2018) The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Cancer Med 7(9):4379–4386. https://doi.org/10.1002/cam4.1707
Franzese C, Franceschini D, Di Brina L et al (2019) Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma. J Urol 201(1):70–76. https://doi.org/10.1016/j.juro.2018.08.049
Guckenberger M, Lievens Y, Bouma AB et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21(1):e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10
Hellman S, Weichselbaum RR (2011) Oligometastases revisited Page_5. Nat Rev Clin Oncol. 2011:378–382
Hosni A, Huang SH, Xu W et al (2017) Distant metastases following postoperative intensity-modulated radiotherapy for oral cavity squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 143(4):368–375. https://doi.org/10.1001/jamaoto.2016.3668
Huang SH, O’Sullivan B (2017) Overview of the 8th edition classification for head and neck cancer. Curr Treat Options Oncol 18(7):40. https://doi.org/10.1007/s11864-017-0484-y
Leeman JE, Li J, Pei X et al (2017) Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol 3(11):1487. https://doi.org/10.1001/jamaoncol.2017.0973
Lievens Y, Guckenberger M, Gomez D et al (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 148:157–166. https://doi.org/10.1016/j.radonc.2020.04.003
Lloyd S, Yu JB, Wilson LD, Decker RH (2011) Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol 34(1):76–81. https://doi.org/10.1097/COC.0b013e3181d26d45
Marcy P-Y, Magné N, Bailet C et al (2004) Liver metastases from head and neck squamous cell carcinomas: radiological and biological features. Onkologie 27(2):157–160. https://doi.org/10.1159/000076905
Margalit DN, Schoenfeld JD, Tishler RB (2015) Radiation oncology—new approaches in squamous cell cancer of the head and neck. Hematol Oncol Clin N Am 29(6):1093–1106. https://doi.org/10.1016/j.hoc.2015.07.008
Milano MT, Katz AW, Muhs AG et al (2007) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2007:650–658. https://doi.org/10.1002/cncr.23209
Oki T, Hishida T, Yoshida J et al (2019) Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators? Eur J Cardiothorac Surg 55(5):942–947. https://doi.org/10.1093/ejcts/ezy384
Ooishi M, Motegi A, Kawashima M et al (2016) Patterns of failure after postoperative intensity-modulated radiotherapy for locally advanced and recurrent head and neck cancer. Jpn J Clin Oncol 46(10):919–927. https://doi.org/10.1093/jjco/hyw095
Otake S, Goto T (2019) Stereotactic radiotherapy for oligometastasis. Cancers (Basel) 11(2):133. https://doi.org/10.3390/cancers11020133
Pasalic D, Betancourt-Cuellar SL, Taku N et al (2020) Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. https://doi.org/10.1002/hed.26117
Rischin D, Harrington KJ, Greil R et al (2019) Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 37(15_suppl):6000–6000. https://doi.org/10.1200/JCO.2019.37.15_suppl.6000
Rusthoven CG, Lanning RM, Jones BL et al (2017) Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol 124(1):139–146. https://doi.org/10.1016/j.radonc.2017.03.019
Sacco AG, Cohen EE (2015) Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 33(29):3305–3313. https://doi.org/10.1200/JCO.2015.62.0963
Schulz D, Wirth M, Piontek G et al (2018a) Improved overall survival in head and neck cancer patients after specific therapy of distant metastases. Eur Arch Oto-Rhino-Laryngol 275(5):1239–1247. https://doi.org/10.1007/s00405-018-4920-9
Schulz D, Wirth M, Piontek G et al (2018b) Improved overall survival in head and neck cancer patients after specific therapy of distant metastases. Eur Arch Otorhinolaryngol 275(5):1239–1247. https://doi.org/10.1007/s00405-018-4920-9
Scorsetti M, Comito T, Clerici E et al (2018) Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol 13(1):234. https://doi.org/10.1186/s13014-018-1185-9
Sun XS, Michel C, Babin E et al (2018) Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. Future Oncol 14(9):877–889. https://doi.org/10.2217/fon-2017-0468
Takes RP, Rinaldo A, Silver CE et al (2012) Distant metastases from head and neck squamous cell carcinoma. Part I Basic aspects. Oral Oncol 48(9):775–779. https://doi.org/10.1016/j.oraloncology.2012.03.013
Vengaloor Thomas T, Packianathan S, Bhanat E et al (2020) Oligometastatic head and neck cancer: Comprehensive review. Head Neck. https://doi.org/10.1002/hed.26144
Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127. https://doi.org/10.1056/NEJMoa0802656
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009;50(1):122S-150S. doi:https://doi.org/10.2967/jnumed.108.057307
Young ER, Diakos E, Khalid-Raja M, Mehanna H (2015) Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis. Clin Otolaryngol 40(3):208–218. https://doi.org/10.1111/coa.12348
No funding was used for the present work.
Conflict of interest
There is no conflict of interest disclosures from any authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Franzese, C., Badalamenti, M., Teriaca, A. et al. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. J Cancer Res Clin Oncol (2021). https://doi.org/10.1007/s00432-021-03518-5
- Head neck cancer
- Salivary gland cancer